Peptides for Muscle Growth and Recovery: What Is Actually Used

Muscle grows because a fiber is loaded hard enough to be signaled to rebuild slightly larger; diet supplies the amino acids. A peptide cannot generate the tension and cannot supply the protein. The most any molecule here can do is change how well the body responds to a stimulus you have already provided, or how soon it is ready for the next one. That is a different claim from "this builds muscle," and any page that blurs the two is selling something.

Your pituitary releases growth hormone in pulses, the largest during deep sleep, prompted by growth-hormone-releasing hormone (GHRH) and restrained by somatostatin. Growth hormone then acts largely by prompting the liver to produce IGF-1, insulin-like growth factor 1, which does most of the anabolic and repair signaling in tissue. A 2000 paper in JAMA described the deep-sleep pulse declining with age alongside slow-wave sleep in healthy men, the observation behind the "recovery" use of this category.

A secretagogue makes your own pituitary release its own growth hormone, under its own feedback control. A 2006 paper in the Journal of Clinical Endocrinology and Metabolism reported that secretion stayed pulsatile in healthy adults even during continuous stimulation with CJC-1295. See peptides vs HGH.

IGF-1 acts at its own receptor on muscle fibers and on the satellite cells that repair them; a 2007 review in In Vivo summarizes that role. Almost all circulating IGF-1 is bound to carrier proteins that control how much is free and for how long, covered in a 2018 review in Frontiers in Endocrinology. That buffering is where IGF-1 LR3 differs from the hormone.

Recovery between sessions is a sleep problem before it is a chemistry problem: the largest growth-hormone pulse and the repair of damaged fibers both happen in slow-wave sleep, and prescribers describe the GH-axis peptides mostly through that lens. The other way a program fails is a strained hamstring or an Achilles that will not tolerate load, which is where BPC-157 and TB-500 belong. Neither builds muscle; a tissue problem that resolves in four weeks rather than eight is four more weeks of training.

CJC-1295 / Ipamorelin is the most commonly prescribed option in this category. CJC-1295 is a GHRH analogue built for a longer duration of action than the natural hormone; a 2006 paper in the Journal of Clinical Endocrinology and Metabolism gave it to healthy adults and reported growth-hormone and IGF-1 raised for days after a dose. Ipamorelin acts through the ghrelin receptor instead; the 1998 paper in the European Journal of Endocrinology that introduced it reported, in animals, growth-hormone release without the cortisol and prolactin rises of older compounds in its class, and a 1999 study in Pharmaceutical Research characterized its response in human volunteers.

The pairing exists because two receptors converge on the same pulse. The human evidence for the combination as prescribed is clinical experience; ipamorelin's only randomized trial in patients, a 2014 study in the International Journal of Colorectal Disease, was intravenous, for post-operative ileus, and did not separate from placebo. It suits people whose limiting factor is sleep and recovery between sessions.

Sermorelin is a 29-amino-acid analogue of GHRH and the shortest-acting option, the one peptide here with a full regulatory history (covered below) and the most adult human data of any GH-axis peptide. A 1992 paper in the Journal of Clinical Endocrinology and Metabolism reported that twice-daily GHRH(1-29) in older men restored growth-hormone and IGF-1 levels toward those of younger men; a 1997 paper in Metabolism studied single nightly injections in healthy elderly men; and a 1997 paper in the Journal of Clinical Endocrinology and Metabolism described long-term administration in age-advanced men and women. Those were older adults, not young athletes; what the studies establish is that the mechanism works in humans and what the side-effect profile looks like. It is the more conservative starting point: see CJC-1295 vs sermorelin.

Tesamorelin is a stabilized GHRH analogue with the strongest randomized evidence on this page, for a specific indication. The 2007 trial in the New England Journal of Medicine and the pooled phase 3 analysis in the Journal of Clinical Endocrinology and Metabolism in 2010 reported reductions in visceral adipose tissue in HIV-infected adults with abdominal fat accumulation; a 2014 trial in JAMA and a 2019 trial in Lancet HIV extended that to liver fat; and a 2012 randomized trial in the Journal of Clinical Endocrinology and Metabolism reported visceral-fat effects in obese adults with reduced growth-hormone secretion. None measured muscle or performance. It suits people whose goal is body composition alongside recovery, and it appears in TITAN, ASCEND and Tesamorelin + Ipamorelin for that reason.

TITAN combines tesamorelin, CJC-1295 and ipamorelin with BPC-157: the full GH-axis stack plus a repair peptide for the tendon and soft-tissue complaints that accumulate under hard training. There is no trial of the combination; the evidence is the evidence for each component, and a physician chooses it when the picture is recovery plus a nagging tissue problem. See what is TITAN.

IGF-1 LR3 is a modified IGF-1 with an extended half-life and reduced binding to the proteins that normally sequester it, meaning more free peptide for longer; a 1992 paper in the Journal of Molecular Endocrinology described the design. It acts at the IGF-1 receptor directly, and it is the only molecule here that signals muscle growth directly.

The muscle research is animal: a 1998 paper in the Journal of Applied Physiology reported hypertrophy after localized IGF-1 infusion into rat muscle, a 2001 paper in Nature Genetics reported that localized IGF-1 expression sustained mass and regeneration in aged mouse muscle, and 1992 work in the Biochemical Journal reported IGF-1 variants were anabolic in rats given a catabolic steroid. There are no randomized human trials of IGF-1 LR3. Native IGF-1's human data is with mecasermin, an approved drug for children with severe IGF-1 deficiency, and a 1987 study in the New England Journal of Medicine reported that it lowered blood glucose in healthy adults. That is the caution a physician thinks about first. See what is IGF-1 LR3.

ASCEND is the GH-axis stack with IGF-1 LR3 included: CJC-1295, ipamorelin and tesamorelin acting upstream at the pituitary, IGF-1 LR3 acting downstream at the tissue. It is the most comprehensive option here and inherits every caution of IGF-1 LR3; a physician prescribing it will want baseline labs and a clear reason the downstream signal is wanted.

BPC-157 + TB-500 is the repair pairing. BPC-157 is a 15-amino-acid fragment of a protein found in human gastric juice, described in animal research as promoting new blood-vessel formation and, in a 2014 paper in Molecules, upregulating growth-hormone receptor expression in tendon fibroblasts. The muscle-specific work: a 2006 paper in the Journal of Orthopaedic Research reported faster functional recovery of a transected quadriceps in rats, a 2008 paper in Surgery Today the same in a crush model, and a 2009 paper in the Journal of Physiology and Pharmacology described blood-vessel formation in healing muscle and tendon.

TB-500 relates to thymosin beta-4 and binds actin, the protein that lets cells migrate; a 2005 review in Trends in Molecular Medicine covers the mechanism, and a 2021 paper in the American Journal of Physiology: Cell Physiology identified thymosin beta-4 as a protein released from human muscle during exercise. A 2010 randomized placebo-controlled study in the Annals of the New York Academy of Sciences gave intravenous thymosin beta-4 to healthy volunteers and reported it well tolerated. A 2026 paper in Joint Diseases and Related Surgery examined the two together in rat Achilles healing. Neither builds muscle; they belong here because a strained hamstring or an inflamed elbow is what ends a training block. See BPC-157 vs TB-500.

The best evidence about what raising growth hormone does in trained people comes from trials of growth hormone itself. A 2008 systematic review in the Annals of Internal Medicine pooled 27 randomized study samples in young, fit adults and reported that growth hormone increased lean body mass by about two kilograms, but that strength and exercise capacity did not appear to improve, lactate during exercise was higher, and treated participants more often had soft-tissue swelling and fatigue. A 2010 randomized placebo-controlled trial in the same journal gave eight weeks of growth hormone to 96 recreational athletes and reported reduced fat mass, a lean-mass increase accounted for by extracellular water, a small increase in sprint capacity that was gone six weeks after stopping, and no change in strength, power or endurance.

Those are studies of injected growth hormone at doses a secretagogue does not reproduce, so they are an upper bound: raising growth hormone in trained adults changed body composition and water more than performance, and a secretagogue working through an intact pituitary should be expected to do less.

Sermorelin has randomized studies in older adults showing restored growth-hormone and IGF-1 levels and body-composition change. Tesamorelin has phase 3 trials showing visceral-fat reduction. Neither measured strength or training performance. CJC-1295 has healthy-volunteer pharmacology; ipamorelin has volunteer pharmacology and one negative surgical trial. A 2018 review in Sexual Medicine Reviews on growth-hormone secretagogues reached the honest conclusion: plausible mechanism, favorable short-term tolerability in the data that exist, and no long-term outcome studies.

All three are preclinical for this use. A 2010 paper in Growth Hormone and IGF Research analyzed a black-market IGF-1 LR3 product and found a manufacturing tag still attached to the peptide, a concrete illustration of why the pharmacy matters. There are no randomized human trials of IGF-1 LR3, BPC-157 or TB-500 for muscle, tendon or ligament injury.

• An effect size for muscle growth in trained adults, for any peptide here. That trial has not been run.
• A human timeline. What patients describe is clinical experience, not a trial endpoint.
• Long-term safety over years of continuous use for CJC-1295, ipamorelin, IGF-1 LR3, BPC-157 or TB-500, which is why bloodwork and physician review are part of treatment.

None are FDA approved for building muscle. GH-axis peptides are prescribed for recovery and sleep quality on a plausible mechanism and a limited evidence base, and anyone quoting a number of pounds of lean mass is making it up. If weight rather than muscle is the goal, see peptides for weight loss.

A state-licensed pharmacy compounding under section 503A may use a bulk substance only if it meets a USP or NF monograph, is a component of an FDA-approved drug product, or appears on the FDA's 503A bulks list; while nominations are evaluated, an interim policy sorts nominated substances into Category 1 (under evaluation), Category 2 (identified significant safety risks) and Category 3 (nominated without adequate support).

Both were placed in Category 2 in September 2023. On 15 April 2026 the FDA announced the removal of twelve peptides from Category 2 after their nominations were withdrawn, BPC-157 and TB-500 among them, and scheduled its Pharmacy Compounding Advisory Committee to consider them. The FDA's safety-risks page, current as of 22 April 2026, lists BPC-157 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" under substances nominated but withdrawn, with six substances remaining in 503A Category 2, none on this page. The committee met on 23–24 July 2026 with BPC-157 (evaluated for ulcerative colitis) and TB-500 (wound healing) on the first day's agenda, and voted 8 yes, 6 no, 1 abstaining to recommend adding each to the 503A bulks list. That is a recommendation; the FDA's final determination is pending as of September 2026.

Both were placed in Category 2 in September 2023 and left it earlier than the April 2026 group, when their nominations were withdrawn in September 2024 and the FDA referred them to its advisory committee. The safety-risks page lists CJC-1295 and ipamorelin acetate among substances nominated but withdrawn; ipamorelin acetate separately remains in Category 2 of the 503B list that governs outsourcing facilities, which is not the route by which a pharmacy fills an individual prescription. On 29 October 2024 the committee voted 0 yes, 12 no, 1 abstaining against adding ipamorelin to the 503A bulks list for the uses evaluated, growth hormone deficiency and post-operative ileus. On 4 December 2024 it voted 0–13 against CJC-1295 (free base) and 1–12 against CJC-1295 acetate, evaluated for growth hormone deficiency. The 503A category list updated 14 May 2026 shows neither in Category 1, 2 or 3, and neither was on the July 2026 agenda. So: no longer flagged as a safety risk, recommended against by the committee for clinical uses that are not the uses they are prescribed for, and awaiting a final FDA determination. A committee vote is not a ban.

Sermorelin acetate was the active ingredient of Geref, approved on 28 December 1990 (NDA 019863) and later discontinued; Drugs@FDA records a Federal Register determination that the product was not withdrawn for safety or effectiveness reasons. It does not appear in any category of the 503A list updated 14 May 2026 and was never part of the Category 2 episode. Its footing for compounding is its history as the active ingredient of an approved drug. There is no currently marketed FDA-approved sermorelin product.

Tesamorelin acetate is the active ingredient of Egrifta, approved on 10 November 2010 (BLA 022505), with the current label approved in March 2025. That label indicates it for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy and states it is not indicated for weight loss management. As a component of an approved drug it was never nominated to the 503A category list and does not appear on it. The approval belongs to that product and that indication, not to a compounded vial.

IGF-1 LR3 does not appear in Category 1, 2 or 3 of the 503A list updated 14 May 2026, is not on the safety-risks page current as of 22 April 2026, and was not on the July 2026 committee agenda; the FDA has published no position on it. Native IGF-1, as mecasermin, is the approved biologic Increlex, indicated for growth failure in children aged two and over with severe primary IGF-1 deficiency, with a warning for severe hypoglycemia including seizures and a contraindication in active or suspected malignancy. IGF-1 LR3 is a different molecule with no approved indication in anyone; none of that drug's evidence transfers to it except the cautions.

For all of these, a compounded medication is prepared by a licensed pharmacy to a physician's prescription for one patient and is never an FDA-approved drug product, whatever its regulatory category. See are peptides FDA approved.

If you are sleeping six hours, eating well under your protein needs, or training without progressive overload, a GH-axis peptide is being asked to compensate for something it cannot, and a physician will ask about all three. Untreated sleep apnea is the one to name: it undermines the deep-sleep pulse the whole category works through.

Growth hormone reduces insulin sensitivity; IGF-1 lowers blood glucose directly. Diabetes, impaired glucose tolerance and any glucose-lowering medication are asked about at intake, and IGF-1 LR3 is not prescribed alongside insulin without a specific plan.

IGF-1 promotes the growth and survival of cells, not only muscle cells. A 2004 systematic review in the Lancet reported that higher circulating IGF-1 was associated with higher risk of prostate, premenopausal breast and colorectal cancer, an association rather than proof of cause, and the approved native product is contraindicated in malignancy. A personal history of cancer is treated as a reason not to prescribe IGF-1 LR3 and a reason for caution with the whole axis; BPC-157's angiogenesis mechanism raises the same conversation.

If you compete under a testing body, check the current prohibited list before your intake. Growth-hormone secretagogues, GHRH analogues and IGF-1 are prohibited at all times in WADA-code sport, and several repair peptides are listed too: see is BPC-157 banned. Tell your physician you compete.

The 2026 Prohibited List, effective 1 January 2026, names CJC-1295, sermorelin and tesamorelin under growth hormone releasing factors, ipamorelin under growth hormone secretagogues and hexarelin under GH-releasing peptides, all in S2.2.4; IGF-1 and its analogues and thymosin-beta-4 and its derivatives including TB-500 under S2.3; and BPC-157 by name under S0, non-approved substances. Every one of those sections is prohibited at all times, in and out of competition.

Sleep is what people mention first with the GH-axis peptides: falling asleep faster, or waking less. Some notice nothing in this window, which is normal. With BPC-157 and TB-500 the early reports are usually background soreness settling rather than the injury changing. Water retention and tingling in the hands are the side effects most likely to appear early with a secretagogue; both are reasons to tell your physician, not to stop on your own.

Patients typically mention reduced soreness the day after hard sessions in this window, and it is where tissue-level change with the repair peptides would be expected if it occurs, based on the animal timelines. Body-composition changes, where they happen at all, come later. IGF-1 is the marker physicians track on this axis, one reason baseline labs are usually requested: see do you need bloodwork before peptides.

Treatment is long-term and refills run on a 28-day rhythm, one vial per fill. No withdrawal or rebound is described for any of these; the 2010 Annals of Internal Medicine trial reported that the sprint-capacity change with growth hormone itself was gone six weeks after stopping, a reasonable expectation for a signal rather than a structural change.